Eli Lilly is celebrating the news that its cyclin-dependent kinase (CDK) 4 & 6 inhibitor Verzenio (ademaciclib) has received approval from the FDA to expand its indication to include the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer in postmenopausal women when used in combination with an aromatase inhibitor (AI).
FDA expands indication of Lilly’s Verzenio in advanced breast cancer
